Queiroz Aline Maria Vasconcelos, Oliveira Johny Wysllas de Freitas, Moreno Cláudia Jassica, Guérin Diego M A, Silva Marcelo Sousa
Immunoparasitology Laboratory, Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.
Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.
Vaccines (Basel). 2021 Mar 5;9(3):220. doi: 10.3390/vaccines9030220.
Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by , spp., and . In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite-host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.
针对锥虫（一类导致被忽视热带病的原生动物，如恰加斯病、利什曼病和昏睡病）的疫苗研究是当前的一项需求。如今，根据现代疫苗学，病毒样颗粒（VLP）技术被应用于许多疫苗中，包括那些与新冠病毒相关的正在研究的疫苗。VLP作为疫苗佐剂的潜在用途为利用原生动物抗原开发针对由锥虫属、利什曼原虫属和布氏锥虫引起的疾病的疫苗提供了机会。在这种背景下，重要的是要考虑这些原生动物在宿主体内的逃避机制以及参与寄生虫-宿主相互作用机制的抗原。因此，VLP的免疫刺激特性可以成为开发和评估新疫苗的重要策略的一部分。这项工作旨在突出VLP作为疫苗佐剂在复杂疾病免疫开发中的潜力，特别是在由锥虫引起的热带病背景下。
Zotero 插件